Mechanism insights into the pleiotropic effects of nobiletin as a potential therapeutic agent on non-alcoholic fatty liver disease (NAFLD)

Non-alcoholic fatty liver disease (NAFLD) is one of the most common liver diseases and is emerging as one of the fastest-growing causes of liver-related deaths worldwide. It is necessary to find strategies to effectively prevent and treat NAFLD, as no definitive drug has been approved. Nobiletin (NO...

Full description

Saved in:
Bibliographic Details
Published in:Biomedicine & pharmacotherapy 2024-04, Vol.173, p.116322-116322, Article 116322
Main Authors: Ran, Qiqi, Gan, Qianrong, Zhu, Ye, Song, Li, Shen, Longyu, Duan, Xinyi, Zhu, Xinyun, Huang, Wei
Format: Article
Language:English
Subjects:
Anti-inflammatory
Anti-oxidation
Drugs, Chinese Herbal - pharmacology
Flavones - pharmacology
Flavones - therapeutic use
Humans
Insulin resistance
Lipid metabolism
Liver
Nobiletin
Non-alcoholic fatty liver disease
Non-alcoholic Fatty Liver Disease - drug therapy
Non-alcoholic Fatty Liver Disease - etiology
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Non-alcoholic fatty liver disease (NAFLD) is one of the most common liver diseases and is emerging as one of the fastest-growing causes of liver-related deaths worldwide. It is necessary to find strategies to effectively prevent and treat NAFLD, as no definitive drug has been approved. Nobiletin (NOB) is the critical active ingredient of Chinese herbal medicines such as Citrus aurantium and Citri Reticulatae Pericarpium, which have anti-inflammatory, antioxidant, lipid regulating, and insulin resistance regulating effects. Numerous studies have demonstrated that NOB can prevent and treat the onset and progression of NAFLD. In this review, the mechanisms of NOB for treating NAFLD have been summarized, hoping to provide a basis for subsequent studies of NOB and to provide a research ground for the development of therapeutic drugs for NAFLD.
ISSN:0753-3322
1950-6007
DOI:10.1016/j.biopha.2024.116322